UK-based pharmaceutical contract developer and manufacturer Quay Pharma has made a number of key appointments as the company continues to experience strong demand both at home and overseas for its specialist services.
In recent months Quay has increased staff numbers by 12, with seven people joining its analytical and manufacturing teams as well as the recruitment of five apprentices, highlighting the company’s commitment to training and development.
In addition, the company has made two senior appointments. Michael Kruidenier has joined the company as European Business Development Manager and Dr Nigel Lord as Analytical Technical Manager.
Kruidenier joins the company from Penn Pharmaceuticals where he was Senior Business Development Manager. He will spearhead Quay’s continued overseas growth.
Lord is an experienced analytical team leader with thorough knowledge of testing, method development and validation across a wide range of disciplines, gained over 15 years with a variety of leading pharma and contract research organisations. He joins Quay after nearly two years at Teva and three years at Almac Sciences.
'These are exciting times for Quay Pharma and our latest recruits will help to ensure we have the skills base both now and in the future to meet client needs,' commented CEO Maireadh Pedersen.
